Glaxo Wellcome Advair
Executive Summary
Commercial introduction is a year away, the company predicted, although the product is coming up on milestones in its FDA review. The salmeterol/fluticasone combination is up for review by an FDA advisory committee Nov. 23 and the user fee review deadline could be as early as January based on the March 1999 NDA submission date. Another important new formulation for Glaxo's asthma product line, the chlorofluorocarbon-free formulation of albuterol (Ventolin HFA) is also in a temporary delay at FDA. The product was deemed "approvable" July 1
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth